A further meta-analysis incorporating the same three ICI RCTs assessed if this variation in response associated with HCC aetiology was observed with molecular targeted therapies too, incorporating pooled data from a further five phase III RCT assessing TKI/anti-VEGF (n = 2083), and concluded that no differences related to aetiology were observed in the response of patients treated with TKI/anti-VEGF therapies [109]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.